EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A ¥4.95, price ¥17.67, upside -72.0%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100005ZB9

HH Broad data Sep 24, 2026

Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A

301246 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥4.95 · Strongly overvalued (−72%)
!Quality 42/100
!Weak Growth (revenue 3y −2.0 %/yr)
✓Solidly profitable · 11.5% net margin (TTM)
!Low debt · negative free cash flow
·0.28% dividend yield
!Trails peers (5/13)
!Moderate moat 45/100
!Weak on past: 23 out of 100
!Weak on dividend: 6 out of 100
Watch Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥41.51 ¥10.68 Fair Value ¥4.95 Mar 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

42‑month range ¥10.68 – ¥41.51 · fair‑value band ¥3.46 – ¥5.17 · the ¥17.67 price screens above the ¥4.95 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A in your weekly email

Every Wednesday you see whether Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally.

Show more

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. It also is involved in the production and sales of triamines, guanine and other products; research and development, production, and sales of pharmaceutical preparations; trading of APIS, pharmaceutical intermediates, organic chemical raw materials, etc.; fluoride salts and other fluorine-containing chemical products; and pharmaceutical wholesale, retail, etc. Hubei Hongyuan Pharmaceutical Technology Co., Ltd. was founded in 2002 and is headquartered in Huanggang, China.

Stock analysis

Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) currently trades at ¥17.67, while our model-based Fair Value estimate is ¥4.95, implying the stock looks roughly 257.0% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥7.47 per share, and 0 of the 13 models we run sit above the ¥17.67 price.

Bear case: the Earnings-Based group reads lowest at ¥3.25, and 13 of the 13 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥3.46 (bear) to ¥5.17 (bull), the price of ¥17.67 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A reported revenue of 1.9B CNY in FY2025 versus 1.6B CNY in FY2021, a compound +5.3%/yr. Reported net income was 119M CNY in FY2025, compounding −29.9%/yr from FY2021.

Key figures

Market cap 11.2B CNY (≈ $1.7B) · P/E ratio 27.6 · P/S ratio 1.69 · EPS (TTM) ¥0.6400 · Dividend yield 0.3% · Net margin 6.1% · Return on equity 5.6% · Return on assets (EBIT) 6.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).

What moves the price

The share trades about 49% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −72%, 301246 screens richer than that median.

Fair Value models

Bear ¥3.46 Fair Value ¥4.95 Bull ¥5.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.4316 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ¥3.95 ¥4.92 ¥6.75 74
Residual Income ¥7.51 ¥7.06 ¥5.36 73
EPV ¥3.08 ¥3.46 ¥3.78 71
All 13 models by family
DCF Models
Owner Earnings ¥3.95 ¥4.92 ¥6.75 74
Earnings-Based
Graham-Dodd ¥2.02 ¥3.25 ¥3.92 64
EPV ¥3.08 ¥3.46 ¥3.78 71
Multiples
P/E Multiple ¥4.91 ¥6.55 ¥8.18 63
P/S Multiple ¥3.79 ¥5.06 ¥6.32 58
P/B Multiple ¥3.79 ¥5.06 ¥6.32 55
EV/EBIT ¥5.95 ¥7.84 ¥9.74 66
EV/EBITDA ¥10.26 ¥13.59 ¥16.92 67
EV/Revenue ¥4.32 ¥6.06 ¥7.80 54
Asset-Based
NCAV (Graham) ¥5.57 ¥7.47 ¥11.15 54
Economic Profit
Residual Income ¥7.51 ¥7.06 ¥5.36 73
ROIC Compounder ¥3.08 ¥3.46 ¥3.78 69
Growth Earnings
Growth-Adj P/E ¥3.46 ¥4.95 ¥6.43 65

Open the full fair value analysis →

Notify me when 301246 reaches fair value

Put 301246 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 42 · Market factors (momentum, volatility) 35

Profitability 22
Margins and returns on capital today
Quality Growth 66
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 28
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 35
Distance to the 52-week high (market factor)
Net Issuance 59
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−26.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−26.6%
Dividend (yield on the price)0.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 9%

301246 screens 257% overvalued. Compare with Merck KGaA →

Compare Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −73% · Bottom 25%
Profitability
Return on equity (TTM) 6% · Below median
Return on assets 3% · Above median
Net margin (TTM) 12% · Above median
Operating margin (TTM) 24% · Top 25%
Growth and dividend
Revenue growth 62% · Top 25%
Dividend yield (TTM) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.08× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 27.6× · Pricier than median
P/B 2.51× · Pricier than median
P/S (TTM) 5.07× · Priciest 25%
EV/EBITDA 23.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)23 · sector 27
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)6 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A · Fair Value
¥4.95 −257%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/301246

Frequently asked questions

Is Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥4.95 versus a price of ¥17.67, about −72% upside (overvalued).
What is the fair value of 301246?
Our model-based fair value for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is ¥4.95 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥17.67.
What is the quality score of 301246?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Our model-based price target is the fair value of ¥4.95 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario ¥3.46, optimistic scenario ¥5.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥4.95, about −72% upside versus a price of ¥17.67 (overvalued). Cautious scenario ¥3.46, optimistic scenario ¥5.17. The calculation is refreshed regularly with new filings.
What is the revenue of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Sep 24, 2026).
Does Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A pay a dividend?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A currently shows a dividend yield of about 0.28% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A it is ¥4.95 per share (as of Sep 24, 2026), against a price of ¥17.67. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 301246 trades above its calculated fair value: price ¥17.67, fair value ¥4.95, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301246?
No. The price is what the market pays today (¥17.67); the fair value is what the company's own numbers justify (¥4.95). For Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A the two are ¥12.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A worth?
The market values Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A at about 11.2B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥17.67; our models calculate a fair value of ¥4.95 per share.
What do the bullish and bearish scenarios say about 301246?
Our models span a range for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A: cautious scenario ¥3.46, base ¥4.95, optimistic ¥5.17 per share (as of Sep 24, 2026, price ¥17.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301246?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A trades at a price-to-earnings ratio of 27.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.95 is built from several models across several years. Other multiples: P/B 2.5, P/S 5.1, EV/EBITDA 23.6.
How solid is the balance sheet of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Balance-sheet figures for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (as of Sep 24, 2026): return on equity 5.6%, debt of 0.08 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 301246 from its 52-week high?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A trades at ¥17.67, about 49% below its 52-week high of ¥34.34 and 25% above the low of ¥14.17 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.95 is for.
Which stocks are comparable to Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A stock attractive at the current price?
The data as of Sep 24, 2026: price ¥17.67, calculated fair value ¥4.95 (−72%), Quality Score 42/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301246 calculated?
We run Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.95, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The closing price on Sep 24, 2026 was ¥17.67. Our model-based fair value is ¥4.95, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥5.17). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A

How large is the market capitalisation of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The market capitalisation of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 11.2B CNY (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The price-to-sales ratio of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 1.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Earnings per share at Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A are ¥0.6400 (price ÷ EPS = P/E 27.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The dividend yield of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 0.3% (payout 7.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The net margin of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The return on equity (ROE) of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
On an EBIT basis the return on assets of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
The operating margin of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Revenue at Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is growing +62.3% versus a year earlier (3y avg −2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)?
Earnings per share at Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A are growing +15.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) generate?
The free cash flow of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A is −341M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A in the live analysis

One click puts Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.